Skip to main content

Advertisement

SpringerLink
Log in

Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

As pharmacokinetics represents a bridge between pharmacological concentrations and clinical regimens, the pharmacokinetic exploration of the therapeutic dose range is a major outcome. This study was aimed at assessing pharmacokinetic linearity of i.v. vinorelbine through an open design with intra-patient dose escalation (3 doses/group). Three groups of six patients received either 20–25–30 mg/m2; or 25–30–35 mg/m2; or 30–35–40 mg/m2. The inclusion criteria were: histologically confirmed tumour with at least one assessable target lesion, age 25–75 years, WHO PS ≤2, normal haematology and biochemistry, life expectancy ≥3 months. The pharmacokinetics was evaluated in both whole blood and plasma over 120 h. Twenty-six patients were recruited and 18 were evaluable for pharmacokinetics. The toxicity consisted in grade ≤3 leucopenia and neutropenia (<20% of courses) and two grade 4 constipation with rapid recovery (2/54 courses). Compared to blood, plasma was demonstrated to underestimate the pharmacokinetic parameters. In blood, the drug total clearance was about 0.6 l/h/kg, with minor contribution of renal clearance, steady state volume of distribution close to 13 l/h/kg, and elimination half-life at about 40 h. A pharmacokinetic linearity was demonstrated up to 40 mg/m2, and even up to 45 mg/m2 when pooling data from another study. A pharmacokinetic–pharmacodynamic relationship was evidenced on leucopenia and neutropenia when pooling the data from the two studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Jacquillat CI, Khayat D, Weill UU, Band PR (1986) Les cancers—guide clinique, pronostique et thérapeutique. Edi Maloine

  2. Chabner BA, Horwitz SB, Clendennin NJ, Purvis JP (1991) Vinca alkaloids. Cancer Chemother Biol Response Modif 12:67–73

    Google Scholar 

  3. Duflos A, Kruczynski A, Barret JM (2002) Novel aspects of natural and modified vinca alkaloids. Curr Med Chem Anti-Canc Agents 2(1):55–70

    Google Scholar 

  4. Corvalan JR, Smith W, Gore VA (1988) Tumour therapy with vinca alkaloids targeted by a hybrid–hybrid monoclonal antibody recognising both CEA and vinca alkaloids. Int J Cancer 2:22–25

    CAS  Google Scholar 

  5. Kruczynski A, Etievant C, Perrin D et al (2002) Characterization of cell death induced by vinflunine, the most recent vinca alkaloid in clinical development. Br J Cancer 86(1):143–150

    Article  CAS  PubMed  Google Scholar 

  6. Kruczynski A, Barret JM, Etievant C et al (1998) Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated vinca alkaloid. Biochem Pharmacol 55(5):635–648

    Article  CAS  PubMed  Google Scholar 

  7. Fedeli L, Colozza M, Boschetti E et al (1989) Pharmacokinetics of Vincristine in cancer patients treated with Nifedipine. Cancer 64(9):1805–1811

    CAS  PubMed  Google Scholar 

  8. Focan C, Doalto L, Mazy V et al (1989) Vindesine en perfusion continue (suivie de Cisplatine) dans le cancer pulmonaire avancé Données chrono-pharmacocinétiques et efficacité clinique. Bull Cancer 76(8):909–912

    CAS  PubMed  Google Scholar 

  9. Jackson DV, Sethi VS, Spurr CL et al (1981) Pharmacokinetics of Vincristine infusion. Cancer Treat Rep 65:1043–1046

    PubMed  Google Scholar 

  10. Ohnuma T, Norter L, Andejazul A, Holland JF (1985) Pharmacokinetics of Vindesine given as an intravenous bolus and 24-hour infusion in humans. Cancer Res 45:464–469

    CAS  PubMed  Google Scholar 

  11. Owellen RJ, Root MA, Hains FO (1977) Pharmacokinetics of Vindesine and Vincristine in Humans. Cancer Res 37:2603–2607

    CAS  PubMed  Google Scholar 

  12. Pinkerton CR, Mcdermott B, Philip T et al (1988) Continuous Vincristine infusion as part of a high dose chemotherapy regimen drug kinetics and toxicity. Cancer Chemother Pharmacol 22:271–274

    CAS  PubMed  Google Scholar 

  13. Rahmani R, Samak R, Bore P, Cano JP (1988) Pharmacocinétique clinique des vinca-alcaloides. Bull Cancer 75:195–200

    CAS  PubMed  Google Scholar 

  14. Rahmani R, Gueritte F, Martin M et al (1986) Comparative pharmacokinetics of antitumor vinca alkaloïds: intravenous bolus injections of Navelbine and related alkaloïds to cancer patient and rats. Chemother Pharmacol 16:223–228

    CAS  PubMed  Google Scholar 

  15. Bore P, Rahmani R, Van Confort J et al (1989) Pharmacokinetics of the new antitumor drug Navelbine in patients. Cancer Chemother Pharmacol 23:247–251

    PubMed  Google Scholar 

  16. Rahmani R, Martin M, Barbet J, Cano JP (1984) Radioimmunoassay and preliminary pharmacokinetics studies in rats of 5′-Noranhydrovinblastine Navelbine. Cancer Res 44:5609–5613

    CAS  PubMed  Google Scholar 

  17. Rahmani R, Bruno R, Iliadis A et al (1987) Clinical pharmacokinetics of the antitumor drug Navelbine (5′-Noranhydrovinblastine). Cancer Res 47:5796–5799

    CAS  PubMed  Google Scholar 

  18. Krikorian A, Rahmani R, Bromet M et al (1989) Pharmacokinetics and metabolism of Navelbine. Semin Oncol 16(4):21–25

    CAS  Google Scholar 

  19. Solere P, Lucas C (1991) Limites analytiques en pharmacocinétique clinique: l’exemple des vinca-alcaloïdes. Bull Cancer 78:775–787

    CAS  PubMed  Google Scholar 

  20. Mangeney P, Andriamialisoa RZ, Lallemand JY et al (1979) A new class of antitumor compounds: 5′-nor and 5′,6′-seco derivatives of vinblastine-type alkaloids. J Org Chem 44:3765–3768

    CAS  Google Scholar 

  21. Mangeney P, Andriamialisoa RZ, Lallemand JY et al (1979) 5′-noranhydrovinblastine prototype of a new class of vinblastine derivatives. Tetrahedron 35:2175–2179

    Article  CAS  Google Scholar 

  22. Marty M, Extra JM, Espie M et al (1989) Advances in vinca-alkaloids: navelbine. Nouv Rev Fr Hematol 31:77–84

    CAS  PubMed  Google Scholar 

  23. Hill BT (2001) Vinflunine, a second generation novel vinca alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers. Curr Pharm Des 7(13):1199–1212

    CAS  PubMed  Google Scholar 

  24. Fellous A, Ohayon R, Vacassin T et al (1989) Biochemical effects of navelbine on tubulin and associated proteins. Semin Oncol 16(4):9–14

    CAS  Google Scholar 

  25. Marquet P, Lachatre G, Debord J et al (1992) Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 42:545–547

    Google Scholar 

  26. Schilling T, Fiebig HH, Kerpel-Fronius S et al (1996) Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients. Invest New Drug 14:371–376

    CAS  PubMed  Google Scholar 

  27. Wargin WA, Lucas VS (1994) The clinical pharmacokinetics of vinorelbine (Navelbine). Semin Oncol 21(5)Suppl 10:21–27

    CAS  Google Scholar 

  28. Leveque D, Jehl F, Quoix E, Monteil H (1993) Pharmacokinetic profile of vinorelbine, a new semi-synthetic vinca alkaloid, determined by high-performance liquid chromatography. Xenobiotica 23(11):1325–1333

    CAS  PubMed  Google Scholar 

  29. Mathe G, Reizenstein P (1985) Phase I pharmacologic study of a new vinca alkaloid: navelbine. Cancer Lett 27:285–293

    Article  CAS  PubMed  Google Scholar 

  30. Krikorian A, Breillout F (1991) Vinorelbine (Navelbine), a new semisynthetic vinca alkaloid. Onkologie 14:7–12

    CAS  PubMed  Google Scholar 

  31. Toso C, Lindley C (1995) Vinorelbine: a novel vinca alkaloid. Am J Health Syst Pharm 52:1287–1303

    CAS  PubMed  Google Scholar 

  32. Crawford J, O’Rourke M, Schiller JH et al (1996) Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small cell lung cancer. J Clin Oncol 14:2774–2784

    CAS  PubMed  Google Scholar 

  33. Depierre A, Chastang C, Quoix E et al (1994) Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 5:37–42

    CAS  Google Scholar 

  34. Furuse K, Kubota K, Kawahara M et al (1994) Japan vinorelbine lung cancer study group: a phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Lung Cancer 11:385–391

    CAS  PubMed  Google Scholar 

  35. Masotti A, Zannini G, Poggi R, Morandini GC (1994) Vinorelbine monochemotherapy in non-small-cell lung cancer: experience in patients with low performance status. Monaldi Arch Chest Dis 49:197–200

    CAS  PubMed  Google Scholar 

  36. Depierre A, Lemarie E, Dabouis G et al (1991) A phase II study of navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 14:115–119

    CAS  PubMed  Google Scholar 

  37. Fossella FV, Devore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens—the TAX 320 non-small cell lung cancer group. J Clin Oncol 18:2354–2362

    CAS  PubMed  Google Scholar 

  38. Pronzato P, Landucci M, Vaira F et al (1994) Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer patients. Anticancer Res 14:1413–1415

    CAS  PubMed  Google Scholar 

  39. Rinaldi M, Della Giulia M, Venturo I et al (1994) Vinorelbine as single agent in the treatment of advanced non-small cell lung cancer. Proceedings of ASCO 1994; Abstract 1212, Dallas, USA

  40. Santoro A, Maiorino L, Santoro M (1994) Second-line vinorelbine in the weekly monochemotherapy for the treatment of advanced non-small cell lung cancer. Lung Cancer 11(1):310

    Google Scholar 

  41. Vogel C, O’Rourke M, Winer E et al (1999) Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 10:397–402

    Article  CAS  PubMed  Google Scholar 

  42. Fumoleau P, Delgado FM, Delozier T et al (1993) Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11:1245–1252

    CAS  PubMed  Google Scholar 

  43. Garcia-Conde J, Lluch A, Martin M et al (1994) Phase II trial of weekly iv vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 5:854–857

    CAS  PubMed  Google Scholar 

  44. Bruno S, Puerto VL, Mickiewicz E et al (1995) Phase II trial of weekly iv vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol 18:392–396

    CAS  PubMed  Google Scholar 

  45. Romero A, Rabinovich MG, Vallejo CT et al (1994) Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12:336–341

    CAS  PubMed  Google Scholar 

  46. Degardin M, Bonneterre J, Hecquet B et al (1994) Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 5:423–426

    Google Scholar 

  47. Gasparini G, Caffo O, Barni S et al (1994) Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 12:2094–2101

    CAS  PubMed  Google Scholar 

  48. Fumoleau P, Delecroix V, Perrocheau G et al (1996) Final results of a phase I dose finding and pharmacokinetic (PK) study of docetaxel in combination with vinorelbine in metastatic breast cancer. Ann Oncol 7(5):126

    Google Scholar 

  49. Romero Acuna L, Langhi M, Perez J et al (1999) Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 17(1):74–81

    PubMed  Google Scholar 

  50. Goedhals L, Vorobiof DA, Bezwoda W et al (1999) Phase II trial of iv vinorelbine and cisplatin in inoperable locally advanced or disseminated non-small-cell lung cancer: the South African experience. Curr Med Res Opin 15(3):185–192

    CAS  PubMed  Google Scholar 

  51. Isokangas OP, Knuuttila A, Halme M et al (1999) Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB–IV non-small-cell lung cancer. Ann Oncol 10:1059–1063

    Article  CAS  PubMed  Google Scholar 

  52. Frasci G, Lorusso V, Panza N et al (2001) Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer 34:S65–S69

    Article  Google Scholar 

  53. Fujushita T, Loda M, Turner RE et al (2003) Sensitivity of non-small cell lung cancer cell lines established from patients treated with prolonged infusions of paclitaxel. Oncology 64(4):399–406

    Article  PubMed  Google Scholar 

  54. Rosen FR, Haraf DJ, Kies MS et al (2003) Multicenter randomised phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation without erythropoietin for advanced head and neck cancer. Clin Cancer Res 9(5):1689–1697

    CAS  PubMed  Google Scholar 

  55. Henningsson A, Sparreboom A, Sandstrom M et al (2003) Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer 39(8):1105–1114

    Article  CAS  PubMed  Google Scholar 

  56. Bissett D, Setanoians A, Cassidy J et al (1993) Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 53:523–527

    Google Scholar 

  57. Extra JM, Rousseau F, Bruno R et al (1993) Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) administered as a short intravenous infusion. Cancer Res 53:1037–1042

    Google Scholar 

  58. Tomiak E, Piccart MJ, Kerger J et al (1994) Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 12:1458–1467

    CAS  PubMed  Google Scholar 

  59. Leveque D, Jehl F (1996) Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet 31(3):184–197

    Google Scholar 

  60. Leveque D, Quoix E, Dumont P et al (1993) Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer. Cancer Chemother Pharmacol 33:176–178

    CAS  PubMed  Google Scholar 

  61. Zorza G, Guyomard C, Joly B et al (2000) In vitro metabolism of vinorelbine in rat, dog, and human. Proceedings of MDO 2000; Abstract 197, Stresa, Italy

  62. Grudé P, Ratanasavanh D, Riché D et al (2000) Characterization of human cytochromes P450 isoenzymes involved in vinorelbine metabolism. Proceedings of MDO 2000; Abstract 179, Stresa, Italy

  63. Focan C, Kreutz F, Leroy I et al (2001) Pharmacokinetics and mass-balance elimination of 3H-vinorelbine following IV and oral administration to patients. Proceedings of AACR 2001; Abstract 2064, New Orleans, USA

  64. Soudon J, Zorza G, Van Heugen JC et al (2001) Search for vinorelbine metabolite activity: an in vitro cytotoxicity study using human ovary and lung cancer cell lines. Proceedings of AACR 2001; Abstract 2909, New Orleans, USA

    Google Scholar 

  65. Puozzo C, Zorza G, Guimbaud R et al (2000) Metabolism of vinorelbine in human: clinical application. Proceedings of AACR 2000; Abstract 1781, San Francisco, USA

    Google Scholar 

  66. Jehl F, Debs J (1990) Determination of navelbine and desacetyl-navelbine in biological fluids by high-performance liquid chromatography. J Chromatogr 525:225–233

    Article  CAS  PubMed  Google Scholar 

  67. Puozzo C, Gridelli C, Riggi M et al (2003) NSCLC in elderly patients: influence of age on NVB oral pharmacokinetics. Proceedings of AACR 2003; Abstract 920, Washington, USA

    Google Scholar 

  68. Puozzo C, Gridelli C, Jaworski M (2002) Pharmacokinetics of navelbine oral in elderly patients. Tumori 88(Suppl 1):75–76

    PubMed  Google Scholar 

  69. Gridelli C, Guida C, Barletta E et al (2000) Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non-small cell lung cancer: a phase I study. Lung Cancer 29(2):131–137

    Article  CAS  PubMed  Google Scholar 

  70. Khayat D, Covelli A, Variol P et al (1995) Phase I and pharmacologic study of intravenous (Iv) vinorelbine in patients (PTS) with solid tumors. Proceedings of ASCO 1995; Abstract 1518, Los Angeles, USA

  71. Urien S, Bree F, Breillout F et al (1993) Vinorelbine high affinity binding to human platelets and lymphocytes: distribution in human blood. Cancer Chemother Pharmacol 32:231–234

    CAS  PubMed  Google Scholar 

  72. Marty M, Fumoleau P, Adenis A et al (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumours. Ann Oncol 12(11):1643–1649

    CAS  PubMed  Google Scholar 

  73. Variol P, Bonneterre J, Marty M et al (2001) Pharmacokinetic/pharmacodynamic relationships of IV and oral Navelbine in phase I patients. Proceedings of ASCO 2001; Abstract 435, San Francisco, USA

Download references

Acknowledgements

The authors would also like to associate Drs Coiffier, Colombat, Gauthier and Rigal to this article for their contribution into patient enrolments.

Author information

Authors and Affiliations

  1. Hôpital Pitié-Salpétrière, Paris, France

    David Khayat & Olivier Rixe

  2. Institut Bergonié, Bordeaux, France

    René Brunet

  3. Institut René Huguenin, St Cloud, France

    Alain Goupil

  4. Institut Claudius Regaud, Toulouse, France

    Roland Bugat

  5. CHU, Nantes, France

    Jean-Luc Harousseau

  6. CHU, Angers, France

    Norbert Ifrah

  7. Department of Oncology Clinical Pharmacokinetics, Institut de Recherche Pierre Fabre, 2me Christian d’Espic, 81106, Castres, France

    Christian Puozzo

Authors
  1. David Khayat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olivier Rixe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. René Brunet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alain Goupil
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Roland Bugat
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean-Luc Harousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Norbert Ifrah
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christian Puozzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Puozzo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khayat, D., Rixe, O., Brunet, R. et al. Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design. Cancer Chemother Pharmacol 54, 193–205 (2004). https://doi.org/10.1007/s00280-004-0794-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-004-0794-1

Keywords

Search

Navigation